Search research articles
Contact Us
Filters
Showing results (21-30 of 91) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2000
Concentrations of galectin-3 in the sera of normal controls and cancer patients
I Iurisci, N Tinari, C Natoli, et al.
Blood
|
October 26, 2000
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo
B Fornarini, C D'Ambrosio, C Natoli, et al.
The Journal of Infectious Diseases
|
October 1, 1991
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression
S Iacobelli, C Natoli, M D'Egidio, et al.
Cancer Research
|
September 1, 1985
A monoclonal antibody (AB/3) reactive with human breast cancer
S Iacobelli, V Natoli, G Scambia, et al.
Clinical and Experimental Immunology
|
February 5, 1999
Human milk 90K (Mac-2 BP): possible protective effects against acute respiratory infections
B Fornarini, S Iacobelli, N Tinari, et al.
Pharmacological Research
|
September 1, 1992
Combinations of biological response modifiers: rationale and clinical responses
C Natoli, B Fiorentino, P Di Stefano, et al.
Anticancer Research
|
November 1, 1995
Chronomodulated infusion of 5-fluorouracil, folinic acid and carboplatin in colorectal cancer: a pilot study
C Natoli, M T Martino, L Irtelli, et al.
FEBS Letters
|
May 20, 2000
Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis
P Matarrese, N Tinari, M L Semeraro, et al.
Cancer Research
|
June 1, 1980
Glucocorticoid receptors and in vitro corticosensitivity in human thymoma
F O Ranelletti, S Iacobelli, M Carmignani, et al.
Journal of Clinical Immunology
|
May 5, 1999
Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura
P Pelliccia, C Natoli, M T Petitti, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 91) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2000
Concentrations of galectin-3 in the sera of normal controls and cancer patients
I Iurisci, N Tinari, C Natoli, et al.
Blood
|
October 26, 2000
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo
B Fornarini, C D'Ambrosio, C Natoli, et al.
The Journal of Infectious Diseases
|
October 1, 1991
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression
S Iacobelli, C Natoli, M D'Egidio, et al.
Cancer Research
|
September 1, 1985
A monoclonal antibody (AB/3) reactive with human breast cancer
S Iacobelli, V Natoli, G Scambia, et al.
Clinical and Experimental Immunology
|
February 5, 1999
Human milk 90K (Mac-2 BP): possible protective effects against acute respiratory infections
B Fornarini, S Iacobelli, N Tinari, et al.
Pharmacological Research
|
September 1, 1992
Combinations of biological response modifiers: rationale and clinical responses
C Natoli, B Fiorentino, P Di Stefano, et al.
Anticancer Research
|
November 1, 1995
Chronomodulated infusion of 5-fluorouracil, folinic acid and carboplatin in colorectal cancer: a pilot study
C Natoli, M T Martino, L Irtelli, et al.
FEBS Letters
|
May 20, 2000
Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis
P Matarrese, N Tinari, M L Semeraro, et al.
Cancer Research
|
June 1, 1980
Glucocorticoid receptors and in vitro corticosensitivity in human thymoma
F O Ranelletti, S Iacobelli, M Carmignani, et al.
Journal of Clinical Immunology
|
May 5, 1999
Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura
P Pelliccia, C Natoli, M T Petitti, et al.
Page
of 10